Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | NAMPT | P43490 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ecabapide SCHEMBL29367862 | 1.00 | MAPT (0.56) | MAPTALDH1A1HPGDALOX12SMN1; SMN2 | |
| Ecabapide SCHEMBL29367974 | 1.00 | MAPT (0.56) | MAPTALDH1A1HPGDALOX12SMN1; SMN2 | |
| SCHEMBL9063062 | 0.91 | MAPK1 (0.54) | MAPTALDH1A1HPGDALOX12SMN1; SMN2 | |
| SCHEMBL9063229 | 0.90 | MAPK1 (0.56) | MAPTALDH1A1HPGDALOX12SMN1; SMN2 | |
| SCHEMBL9769115 | 0.89 | KMT2A (0.56) | MAPTALDH1A1HPGDALOX12SMN1; SMN2 | |
| Water SCHEMBL9769056 | 0.88 | KMT2A (0.55) | MAPTALDH1A1HPGDALOX12SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL11274170 | 0.88 | KMT2A (0.55) | MAPTALDH1A1HPGDALOX12SMN1; SMN2 | |
| SCHEMBL9063049 | 0.87 | KMT2A (0.53) | MAPTALDH1A1HPGDALOX12SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL6370914 | 0.85 | F2 (0.55) | MAPTALDH1A1HPGDALOX12SMN1; SMN2 | |
| SCHEMBL11282670 | 0.84 | ERCC1 (0.65) | MAPTALDH1A1SMN1; SMN2KMT2AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 338 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| EP-2560634-A1 | NITRIC OXIDE RELEASING PRODRUGS OF THERAPEUTIC AGENTS | Piramal Enterprises Limited (IN) | 2013-02-27 | — | — | EP | claimed |
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | claimed |
| WO-2011132171-A1 | NITRIC OXIDE RELEASING PRODRUGS OF THERAPEUTIC AGENTS | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2011-10-27 | — | — | WO | claimed |
| US-20110263526-A1 | Nitric Oxide Releasing Prodrugs of Therapeutic Agents | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2011-10-27 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| WO-2010038241-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING OF PROTON PUMP INHIBITOR, PROKINETIC AGENT AND ALGINIC ACID | PANACEA BIOTEC LIMITED (IN) | 2010-04-08 | — | — | WO | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| EP-1596838-A2 | ONCE A DAY ORALLY ADMINISTERED PHARMACEUTICAL COMPOSITIONS COMPRISING A PROTON PUMP INHIBITOR AND A PROKINETIC AGENT | Torrent Pharmaceuticals Ltd (IN) | 2005-11-23 | — | — | EP | claimed |
| WO-2004071374-A2 | ONCE A DAY ORALLY ADMINISTERED PHARMACEUTICAL COMPOSITIONS | TORRENT PHARMACEUTICALS LIMITED (IN) | 2004-08-26 | — | — | WO | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| CN-1343128-A | Medicinal compositions | DAICHI PHARMACEUTICAL CO LTD (JP) | 2002-04-03 | — | — | CN | claimed |
| EP-0697215-A1 | DIGESTIVE SYMPTOM AMELIORANT | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1996-02-21 | — | — | EP | claimed |
| US-4985595-A | Anti-peptic Ulcer Agents | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1991-01-15 | — | — | US | claimed |
| EP-0185368-B1 | AMINOBENZAMIDE DERIVATIVES | DAIICHI SEIYAKU CO., LTD. (JP) | 1990-06-06 | — | — | EP | claimed |
| EP-0185368-A2 | Aminobenzamide derivatives | DAIICHI SEIYAKU CO., LTD. (JP) | 1986-06-25 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263526-A1 | Nitric Oxide Releasing Prodrugs of Therapeutic Agents | NOS2, NOS1, NOS3 | MAPT 4304/4885ALDH1A1 204/4885HPGD 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.